Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA internal analgesics

This article was originally published in The Tan Sheet

Executive Summary

Comment period on agency's proposal to amend internal analgesics tentative final monograph to include ibuprofen reopened until Sept. 2, FDA says in 1June 4 Federal Register notice. In October, Wyeth requested additional time to evaluate labeling suggestions made during NDAC meeting on internal analgesic products (2"The Tan Sheet" Oct. 28, 2002, In Brief). Firm also said it might conduct consumer research on information relevant to crafting appropriate label. FDA "acknowledges that additional time may be beneficial to fully evaluate and respond to the issues." Agency proposed the amendment in August (3"The Tan Sheet" Aug. 26, 2002, p. 3)...
Advertisement

Related Content

Wyeth ibuprofen comments
Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion

Topics

Advertisement
UsernamePublicRestriction

Register

PS095552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel